Literature DB >> 11821172

Activity of cefditoren against beta-lactamase-positive and -negative Haemophilus influenzae and Moraxella catarrhalis.

James A Karlowsky1, Ian A Critchley, Deborah C Draghi, Mark E Jones, Clyde Thornsberry, Daniel F Sahm.   

Abstract

Cefditoren is a novel broad-spectrum oral cephalosporin. To determine the influence of beta-lactamase production on cefditoren activity, 1,170 H. influenzae and 641 M. catarrhalis isolated during 2000 were tested by NCCLS broth microdilution methodology (M7-A5, 2000). Against H. influenzae the potency of cefditoren (MIC(90,) 0.015 microg/mL) was similar to that of ceftriaxone (MIC(90,) < or = 0.015 microg/mL) and levofloxacin (MIC(90,) 0.015 microg/mL), and its MIC distribution was unaffected by beta-lactamase production. In comparison, the beta-lactamase status of M. catarrhalis affected the potency of all beta-lactams tested, including cefditoren, as well as trimethoprim-sulfamethoxazole. However, regardless of the presence of beta-lactamase, cefditoren demonstrated potent activity, as concentrations of 0.5 and 1 microg/mL inhibited 93.1 and 100% of M. catarrhalis isolates, respectively. We conclude that cefditoren is highly active in vitro against beta-lactamase-positive H. influenzae and M. catarrhalis.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11821172     DOI: 10.1016/s0732-8893(01)00331-5

Source DB:  PubMed          Journal:  Diagn Microbiol Infect Dis        ISSN: 0732-8893            Impact factor:   2.803


  3 in total

Review 1.  Cefditoren pivoxil: a review of its use in the treatment of bacterial infections.

Authors:  Keri Wellington; Monique P Curran
Journal:  Drugs       Date:  2004       Impact factor: 9.546

2.  Use of population pharmacokinetic modeling and Monte Carlo simulation to describe the pharmacodynamic profile of cefditoren in plasma and epithelial lining fluid.

Authors:  Thomas P Lodise; Martina Kinzig-Schippers; George L Drusano; Ulrich Loos; Friedrich Vogel; Jürgen Bulitta; Markus Hinder; Fritz Sörgel
Journal:  Antimicrob Agents Chemother       Date:  2007-05-07       Impact factor: 5.191

3.  Development of a disk diffusion method for testing Moraxella catarrhalis susceptibility using clinical and laboratory standards institute methods: a SENTRY antimicrobial surveillance program report.

Authors:  Jan M Bell; John D Turnidge; Ronald N Jones
Journal:  J Clin Microbiol       Date:  2009-05-20       Impact factor: 5.948

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.